Session » Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster II

Date: Tuesday, November 15, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2867

Aberrant Epigenetic Alterations at the Promoter up-Regulate cAMP Responsive Element Modulator Alpha in CD4+ T Cells from Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2865

Apoptotic Microparticles, but Not Exosomes, Induce an Inflammatory Response in Synoviocytes

9:00AM-11:00AM: Abstract Number: 2886

Associations Between Type I Interferon and Antiphospholipid Antibody Status Differ Between Ancestral Backgrounds

9:00AM-11:00AM: Abstract Number: 2873

B-Cell activating Factor Genetic Variants in Systemic Lupus Erythematosus and Lupus Related Atherosclerosis

9:00AM-11:00AM: Abstract Number: 2874

CD16+monocytes Are Enriched and Functionally Exacerbated in Driving B Cell Activation Under Systemic Lupus Erythematosus Condition

9:00AM-11:00AM: Abstract Number: 2882

CD4+ T Helper Cells and Regulatory T Cells in Active Lupus Nephritis – an Imbalance Towards a Predominant Th1 Response?

9:00AM-11:00AM: Abstract Number: 2884

Cell-Type Specific Epigenetic Features of Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2869

Critical Roles of IRAK4 Kinase Activity in Inflammation but Not B Cell Response in SLE

9:00AM-11:00AM: Abstract Number: 2875

Depressed Serum IgM Levels in SLE Are Restricted to Defined Subgroups

9:00AM-11:00AM: Abstract Number: 2880

Distinct Metabolic Pathways Regulate Lipid Antigen Presentation By Monocytes and B Cells: Implications for SLE Patients with Pre-Clinical Atherosclerotic Plaque

9:00AM-11:00AM: Abstract Number: 2885

Expression Levels and Function of the Inhibitory Molecule, Immunoglobulin like Transcript 7 (ILT7), Are Decreased on Circulating Plasmacytoid Dendritic Cells in SLE Patients with High ANA Titers

9:00AM-11:00AM: Abstract Number: 2879

Genome-Wide Pathway Analysis Reveals That VEGF Genetic Pathway Is Associated with Oral Ulcers in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2863

High Frequency of Terminally Differentiated CD8+ T Cells Characterize Systemic Lupus Erythematosus Patients with Renal Involvement

9:00AM-11:00AM: Abstract Number: 2864

Identifying Dysregulated and Co-Dysregulated Markers in Systemic Lupus Erythematosus Using Multi-Modal Biomarker Data from a Large Pre-Clinical Study

9:00AM-11:00AM: Abstract Number: 2866

Lupus HDL Induces Pro-Inflammatory Responses in Macrophages By Binding LOX1Rand Failing to Promote ATF3 Activity

9:00AM-11:00AM: Abstract Number: 2878

Major Lymphocyte Populations Share a Common Interferon Signature but Express Cell Type-Specific Interferon Pathway Genes in SLE

9:00AM-11:00AM: Abstract Number: 2868

NK Cell Characterization in Patients with Systemic Lupus Erythematosus: Increased Frequency of Ki67+ NK Cells Associated with Disease Activity and Type I Interferon Signature

9:00AM-11:00AM: Abstract Number: 2877

Notch Ligand Delta-like Ligand 4 (DLL4) Expression on Dendritic Cells Is Increased in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2870

Overexpression of EZH2 at the microRNA-142 Regulatory Region Contributes to Down-Regulation of microRNA-142-3p/5p in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2861

Proportions of Circulating Follicular Helper T Cells and Complement Levels, White Blood Cell Counts, and Skin Manifestations in Patients with Active Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2881

Reduced Hippocampal-Thalamic Fiber Tracts in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2876

SLE Serum Impairs NO Production in Huvecs through Induction of eNOS Uncoupling

9:00AM-11:00AM: Abstract Number: 2872

SLE Subjects Express High Levels of Intracellular Interferon-β That Acts in an Autocrine Fashion to Promote Survival of Transitional Stage B Cells

9:00AM-11:00AM: Abstract Number: 2883

The CD4+CD52low T Cell Contributes to the Development of Systemic Lupus Erythematosus through the CCR8/TARC Pathway

9:00AM-11:00AM: Abstract Number: 2871

Unaffected Lupus Relatives Are Distinguished from SLE Patients and Unaffected Individuals Not Related to SLE Patients By Lupus-Specific Connective Tissue Disease Questionnaire Scores, Autoantibodies, and Distinct Soluble Mediators

9:00AM-11:00AM: Abstract Number: 2862

Whole Blood Phenotyping and Innate and Adaptive Stimulation Reveal Unique Differences in Granulocytes and Innate Pathways of African American SLE Patients with Variable Disease Activity

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].